Moderna stock price could surge another 45% on COVID-19 vaccine - Business Insider

  • 📰 BusinessInsider
  • ⏱ Reading Time:
  • 23 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 13%
  • Publisher: 51%

日本 ニュース ニュース

日本 最新ニュース,日本 見出し

Moderna is poised to surge another 45% in the next year, COVID-19 vaccine could generate more than $5 billion in annual sales, Jefferies says

is set to surge higher even after its epic 220% rally so far this year, according to Jefferies.

The bullish rating hinges on Moderna's COVID-19 vaccine working and resulting in large government supply contracts, Jefferies equity analyst Michael Yee wrote in a Monday note. In the first full year of sales of its potential vaccine, Jefferies' model shows it could bring in $2 billion worldwide if roughly 50 million people get the vaccine at $50. This could grow to a peak of $5 billion between 2025 and 2026, according to the note.

このニュースをすぐに読めるように要約しました。ニュースに興味がある場合は、ここで全文を読むことができます。 続きを読む:

 /  🏆 729. in JP
 

コメントありがとうございます。コメントは審査後に公開されます。

English press release of Dr. Zelenko new study. Please share. Treat early and live. Combo works.

日本 最新ニュース, 日本 見出し

Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。

ICU head in Bergamo, Italy, says COVID-19 causing 'chronic damage' - Business InsiderBusiness Insider is a fast-growing business site with deep financial, media, tech, and other industry verticals. Launched in 2007, the site is now the largest business news site on the web.
ソース: BusinessInsider - 🏆 729. / 51 続きを読む »